Ocumension jumps most in three months on China nod for new drug application
03/07/2026 06:37
BUZZ-Ocumension jumps most in three months on China nod for new drug application ** Shares of Ocumension Therapeutics 1477.HK jump 11.3% to HK$5.23, on track for the biggest one-day pct rise since April 1
** Stock touches the highest level June 15
** The ophthalmic pharmaceuticals developer says China's National Medical Products Administration has approved new drug application for OT-502 that treats post-operative ocular inflammation
** To date, OT-502 is the first and only single-dose, sustained-release intraocular steroid to treat postoperative inflammation that has been approved by the U.S. FDA - co
** YTD, stock down 32.2%, Hang Seng Biotech Index .HSBIO down 3.5%
($1 = 6.7808 Chinese yuan renminbi)
(Reporting by Donny Kwok)
Recent news on Ocumension Therapeutics
See all newsBrief: Ocumension Therapeutics Says NMPA Accepts NDA For OT-301 (NCX 470, Bimatoprost Grenod)
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application